Bone composition: relationship to bone fragility and antiosteoporotic drug effects.
Bone composition: relationship to bone fragility and antiosteoporotic drug effects.
复制标题
DOI：
10.1038/bonekey.2013.181
复制
发表时间：
2013-01-01
期刊：
影响因子：
--
通讯作者：
Boskey, Adele L
中科院分区：
文献类型：
--
作者：
Boskey, Adele L
骨的组成可以用矿物相、羟基磷灰石、有机相（由I型胶原、非胶原蛋白、其他成分和水组成）来描述。这些不同组分的相对比例随年龄、部位、性别、疾病和治疗而变化。任何药物治疗都可能改变骨骼的成分。然而，这篇综述将只涉及那些用于治疗或预防骨骼疾病的药物：特别是脆性骨折，以及它们改变成分的方式。由于骨是一种异质组织，因此必须从化学组成、化学成分的性质及其在不断变化的骨基质中的分布方面来讨论骨的组成。在这篇综述中，重点放在组成的变化作为年龄和各种骨骼疾病，特别是骨质疏松症的函数上。这表明，虽然一些抗骨质疏松药物可以和修改的组成，其对骨强度的积极影响可能是由负面的平衡。
The composition of a bone can be described in terms of the mineral phase, hydroxyapatite, the organic phase, which consists of collagen type I, noncollagenous proteins, other components and water. The relative proportions of these various components vary with age, site, gender, disease and treatment. Any drug therapy could change the composition of a bone. This review, however, will only address those pharmaceuticals used to treat or prevent diseases of bone: fragility fractures in particular, and the way they can alter the composition. As bone is a heterogeneous tissue, its composition must be discussed in terms of the chemical makeup, properties of its chemical constituents and their distributions in the ever-changing bone matrix. Emphasis, in this review, is placed on changes in composition as a function of age and various diseases of bone, particularly osteoporosis. It is suggested that while some of the antiosteoporotic drugs can and do modify composition, their positive effects on bone strength may be balanced by negative ones.